Bharat Parenterals MD, chairman, board of directors and AGM
NSE: BPLPHARMABSE: 541096Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,776.00.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,165 Cr1,597th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Owners' profit not stated
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 3.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.06%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- −5.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,08940.3% delivered
Bharat Parenterals board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Chairperson and managing directorBHARATKUMAR RAMESHCHANDRA DESAIRelated to the promoter
- Company Secretary and Compliance OfficerSHARMIN SONI
6 directors3 independent2 executive1 non-executive
- BHARATKUMAR RAMESHCHANDRA DESAI · Chairperson and managing directorExecutive · joined Sep 1992 · reappointed Oct 2024 · 1 listed board
- HEMANG JAYENDRABHAI SHAHExecutive · joined Jul 2010 · reappointed Sep 2026 · 1 listed board · 2 committee seats
- SHAILESHKUMAR GHABHAWALAIndependent · joined Aug 2017 · reappointed Feb 2022 · 109 months as independent · 1 listed board · 1 as independent
- ZANKHANA BIMALKUMAR SHETHIndependent · joined Aug 2018 · reappointed Aug 2023 · 97 months as independent · 1 listed board · 1 as independent · 2 committee seats
- MUKESHBHAI JIVRAJBHAI PATELIndependent · joined Sep 2020 · reappointed Sep 2025 · 72 months as independent · 1 listed board · 1 as independent
- ALKESH JAYANTILAL SHAHNon-executive · joined Jul 2025 · 1 listed board
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- SANJAY PARASMAL SHAH, left 28 Jul 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 29 Sep 20266 of 6 present3 independent · 54 days in between
- 5 Aug 20266 of 6 present3 independent · 34 days in between
- 1 Jul 20266 of 6 present3 independent · 29 days in between
- 1 Jun 20266 of 6 present3 independent · 13 days in between
1 earlier meeting
- 18 May 20265 of 6 present3 independent
Audit Committee
Chair SHAILESHKUMAR GHABHAWALA
ZANKHANA BIMALKUMAR SHETH, HEMANG JAYENDRABHAI SHAH
- 26 Sep 20263 of 3 present2 independent · 51 days in between
- 5 Aug 20263 of 3 present2 independent · 78 days in between
- 18 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair SHAILESHKUMAR GHABHAWALA
ZANKHANA BIMALKUMAR SHETH, MUKESHBHAI JIVRAJBHAI PATEL
- 5 Aug 20263 of 3 present3 independent · 78 days in between
- 18 May 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair SHAILESHKUMAR GHABHAWALA
ZANKHANA BIMALKUMAR SHETH, HEMANG JAYENDRABHAI SHAH
- 5 Aug 20263 of 3 present2 independent · 78 days in between
- 18 May 20263 of 3 present2 independent
Corporate Social Responsibility Committee
Chair BHARATKUMAR RAMESHCHANDRA DESAI
HEMANG JAYENDRABHAI SHAH, SHAILESHKUMAR GHABHAWALA, ZANKHANA BIMALKUMAR SHETH
- 5 Aug 20264 of 4 present2 independent · 78 days in between
- 18 May 20264 of 4 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- M/s Shah Mehta & BakshiPeer-review certificate valid to Jul 2028
1 earlier auditor
- M/s. Shah Mehta and BakshiNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Bharat Parenterals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Bharat Parenterals dividend history
Annual general meeting, 19 Sep 2026
3,108 shareholders on the register on 12 Sep 2026; present: 5 promoters and 30 others; votes counted by Jigar Trivedi / Jigar Trivedi & Co..The company's voting result (opens in a new tab)
TO RECEIVE, CONSIDER AND ADOPT THE AUDITED FINANCIAL STATEMENTS (INCLUDING CONSOLIDATED FINANCIAL STATEMENTS) OF THE COMPANY FOR THE FINANCIAL YEAR ENDED MARCH 31, 2026 TOGETHER WITH THE REPORTS OF THE DIRECTORS AND THE INDEPENDENT AUDITORS THEREON.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
- TO DECLARE A FINAL DIVIDEND FOR THE FINANCIAL YEAR ENDED ON MARCH 31, 2026.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
- TO APPROVE THE APPOINTMENT OF MR. HEMANG SHAH (DIN: 03024324), WHO RETIRES BY ROTATION AND BEING ELIGIBLE, OFFERS HIMSELF FOR REAPPOINTMENTOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
- TO REAPPOINTMENT OF MR. HEMANG SHAH (DIN: 03024324) AS AN EXECUTIVE DIRECTOR OF THE COMPANYOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
- TO APPROVE AND RATIFY THE REMUNERATION PAYABLE TO M/S. CMA CHETAN GANDHI, COST ACCOUNTANTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDING MARCH 31, 2027.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
- TO APPROVE RELATED PARTY TRANSACTIONSOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 69.84% · promoters 99.92% · institutions 0.00% · other public 8.20%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Sep 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesMay 2024 | 95.60 | Capital Adequacy for Expansion of Business | 7.17 | 7.17 | No |
| Preferential IssuesMay 2024 | 95.60 | Investment in Subsidiary Company | 76.48 | 76.48 | No |
| Preferential IssuesMay 2024 | 95.60 | Funds for General Corporate Purposes of the Company | 11.95 | 11.95 | No |